Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 5;22:147. doi: 10.1186/s12885-022-09184-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Flow-MRD monitoring of patients reaching CR/sCR during their course, identifies flow-MRD positive patients over time before progression is clinically observed, while flow-MRD negative maintain progression-free regardless their initial RS status. Data points for longitudinal flow-MRD assessment (circles) after inclusion from 20 patients with ≥3 flow-MRD BM samples (inclusive 1st RA), analysed until clinical progression or until date of last clinical contact are lined up over time. Inclusion, RS, progression and date of last contact (until censoring) are indicated. Abbreviations: PR: Partial response. VGPR: Very good PR. CR: Complete response. SCR: stringent CR. INCL: Date of inclusion into the MRD-study. PROG: Date of clinical progression. Flow-MRD: MRD assessment using MFC. RA = Response assessment. RS: Response status (clinical). Patient ID: Patient identification number. SFLCr: Serum free light chain ratio. MFC: Multiparamteric flow cytometry. mPC: Malignant plasma cells. DLC: Date of last contact or censoring date. (*): Patients progressed with extramedullary disease. n.d.: 1st RA BM sample not received or flow-MRD status not determined